3 results
8-K
EX-99.1
GLTO
Galecto Inc
23 Oct 23
Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial
9:00am
facilitates tumor escape from the immune response by suppressing essential T-cell functions and activating tumor-protecting macrophages.
Evidence
8-K
EX-99.1
GLTO
Galecto Inc
5 Jan 22
Regulation FD Disclosure
4:02pm
Increased growth, progression, angiogenesis and metastasis Head and Neck Cancer Cell proliferation, anti-apoptosis, immune escape Gastric Cancer
- Prev
- 1
- Next